Join AsymBio at 4th ADC Analytical Development Summit in Boston on April 28-30, 2025! AsymBio will take this chance to show how cutting-edge analytical tools are revolutionizing bioassays, enhancing potency measurement, and unlocking deeper insights into ADC mechanisms of action.

Meet AsymBio Team at Booth 635 in Festival of Biologics San Diego 2025!With over 2,000 attendees, 300 speakers, more than 120 exhibitors, and 50 startups in FOB San Diego 2025, AsymBio will showcase industry leading CDMO solutions! Whether you’re tackling complex PD challenges or scaling up producti...

AsymBio, the subsidiary of Asymchem Laboratories (Stock Code: 002821.SZ/6821.HK), announced the official inauguration of its CDMO base in Fengxian, Shanghai. This facility will provide late-stage clinical and commercial manufacturing services for antibodies and bioconjugates.Spanning over 120,000 sq...

Mark your calendars for March 3rd–6th, 2025. AsymBio will be at Booth #36 to showcase cutting-edge integrated solutions for your bioconjugates! Whether you’re tackling complex PD challenges or scaling up production, our experts are ready to collaborate and innovate with you. Do not miss this chance ...

Axcynsis Therapeutics, a strategic partner of AsymBio, announced the clearance of its Investigational New Drug application (IND) by the United States Food and Drug Administration (FDA) of AT03-65 for the treatment of patients with CLDN-6 positive solid tumors. Axcynsis is planning to initiate a Phas...

Novatim, a strategic partner of AsymBio, announced U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the worlds 𝗳𝗶𝗿𝘀𝘁 𝗔𝗗𝗖 with a 𝗯𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗻𝗮𝗻𝗼𝗯𝗼𝗱𝘆 targeting MET and EGFR. With this IND approval, Novatim will be able to...

AsymBio, a leading biologics Contract Development and Manufacturing Organization (CDMO), took center stage at the World ADC San Diego 2024.During the conference, we hosted a drinks reception and Dr. Weibin Chen gave a presentation on . It was a great opportunities to meet and connect with the expert...

We are thrilled to announce that AsymBio has been shortlisted in the category of the Best Contract Manufacturing Provider for the 11th World ADC Awards!

AsymBio, a leading China-based biologics Contract Development and Manufacturing Organization (CDMO), is excited to announce that it has successfully passed the European Union Qualified Person (QP) Audit. This achievement underscores AsymBios adherence to stringent guidelines and regulations by the E...

AsymBio, a leading biologics Contract Development and Manufacturing Organization (CDMO), took center stage at the Antibody Engineering and Brian Dwyer, Ph.D, Director of Business Development, engaged with industry leaders and experts throughout the conference.AsymBio highlighted its deep expertise ...